Long-Term Efficacy and Potential Predictors of Tralokinumab Dose Optimization in Elderly Patients: A Multicentre Study.

introductionAtopic dermatitis (AD) is a chronic inflammatory skin disease that significantly affects elderly patients, particularly those with multiple comorbidities. Tralokinumab, an IL- 13-neutralizing monoclonal antibody, is approved at 300 mg every 2 weeks (Q2 W), with the option to optimize to a once-monthly (Q4 W) regimen in patients achieving optimal disease control. This study evaluates its long-term efficacy and safety in elderly patients (> 65 years) and explores predictors of treatment response and optimization.

methodsA retrospective multicenter study was conducted across four Spanish hospitals, including patients > 65 years old with moderate-to-severe AD treated with tralokinumab. The primary endpoints were treatment efficacy and safety at weeks 16, 24, and 52, while secondary endpoints included identifying predictors of treatment response and successful dose optimization.

resultsA total of 24 patients (mean age 75.3 ± 8.4 years, 45.8% male) were included. A significant reduction in EASI (Eczema Area and Severity Index), Pruritus NRS (Numerical Rating Scale), DLQI (Dermatology Life Quality Index), and BSA (Body Surface Area) scores was observed at weeks 16, 24, and 52 (p < 0.05). Dose optimization to 300 mg Q4 W was achieved in 25% of patients. Male sex (p = 0.042) and higher baseline EASI (p = 0.004) were associated with poorer early response, whereas a shorter time to systemic treatment initiation (p = 0.023) increased the likelihood of dose optimization. No serious adverse events or neoplasm progression were reported.

conclusionTralokinumab demonstrated sustained efficacy and safety in elderly patients with moderate-to-severe AD, even with multiple comorbidities. Dose optimization to Q4 W was feasible in a subset of patients. Early systemic treatment initiation was linked to better outcomes, emphasizing the need for proactive disease management.